Company: ATRA
Filing Date: 2025-03-07
Form Type: 10-K
Source: 0000950170-25-035507
Chunk: 178

Company: Atara Biotherapeutics, Inc.
Filing Date: 2025-03-07
Form: 10-K
Item: Item 1B
Chunk 178
---
,444

    $
    122,940

    $
    (45,496
    )

    Medical and safety expense

    44,138

    67,445

    (23,307
    )

    Regulatory and quality expense

    29,901

    34,400

    (4,499
    )

    Total research and development expenses
     
    $
    151,483

    $
    224,785

    $
    (73,302
    )

Platform sciences, development and operations expense were $77.4 million in 2024 as compared to $122.9 million in 2023. The decrease in 2024 was primarily due to lower payroll and related costs, driven by the November 2023 and January 2024 reductions in force and the termination of the ATA188 program after the Phase 2 EMBOLD study did not meet its primary endpoint.

Medical and safety expense were $44.1 million in 2024 as compared to $67.4 million in 2023. The decrease in 2024 is primarily due to lower payroll and related costs, driven by the November 2023 and January 2024 reductions in force and the close out of the ATA188 Phase 2 EMBOLD study after it did not meet its primary endpoint. 

Regulatory and quality expense were $29.9 million in 2024 as compared to $34.4 million in 2023. The decrease in 2024 was primarily driven by lower payroll and related costs, driven by the November 2023 and January 2024 reductions in force. This decrease was partially offset by increased costs related to activities supporting the tab-cel BLA submission.

General and administrative expenses 

General and administrative expenses for the periods indicated were as follows:

    Year ended December 31,

    2024

    2023

    (Decrease) Increase

    (in thousands)

    General and administrative expenses
     
    $
    39,886

    $
    50,908

    $
    (11,022
    )

General and administrative expenses were $39.9 million in 2024 as compared to $50.9 million in 2023. The decrease in 2024 was primarily driven by lower payroll and related costs as a result of the November 2023 and January 2024 reductions in force. 

Other income (expense), net

    Year ended December 31,